Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00278863
Status:
COMPLETED
Last Update Posted:
2014-02-25
First Post:
2006-01-17
Brief Title:
Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer AGC Randomized Trial
Sponsor:
Asan Medical Center
Organization:
Asan Medical Center
Study Overview
Official Title:
Randomized Multicenter Phase II Trial of Capecitabine Versus S-1 as First-line Treatment in Elderly Patients With Advanced or Recurrent Unresectable Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A significant proportion of advanced gastric cancer AGC occurs in individuals 65 years of age and older In addition patient delay in seeking care for symptoms results in diagnosis at a more advanced stage than that seen in younger individuals However clinical trials on gastric cancer rarely have been available to the elderly Recently oral 5-FU pro-drugs which have been reported to have clinically significant response rates and survival with mild or negligible toxicities have been widely used for the patients with AGC However few studies have been conducted in elderly patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None